{"name": "Cardioxyl Pharmaceuticals",
 "permalink": "cardioxyl-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/cardioxyl-pharmaceuticals",
 "homepage_url": "http://www.cardioxyl.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2005,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@cardioxyl.com",
 "phone_number": "(919) 869-8585",
 "description": "Clinical stage biopharmaceutical company",
 "created_at": "Tue Aug 03 01:42:48 UTC 2010",
 "updated_at": "Wed Mar 13 13:10:37 UTC 2013",
 "overview": "\u003Cp\u003ECardioxyl Pharmaceuticals is a privately held, clinical stage biopharmaceutical company developing therapies for the treatment of cardiovascular disease, focusing on the discovery, development and commercialization of novel technologies for disease areas where current therapies don\u0026#8217;t exist, are ineffective or are inadequate.\u003C/p\u003E\n\n\u003Cp\u003ECardioxyl has developed industry-leading expertise in the chemistry, biology and clinical applications of nitroxyl technology. The company\u0026#8217;s core nitroxyl platform has generated several pre-clinical and clinical candidates including the company\u0026#8217;s lead compound, CXL-1020, currently in clinical development for Acute Decompensated Heart Failure, the most common cause of hospitalization for patients older than 65 years of age.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       43],
      "assets/images/resized/0010/8066/108066v1-max-150x150.png"],
     [[206,
       60],
      "assets/images/resized/0010/8066/108066v1-max-250x250.png"],
     [[206,
       60],
      "assets/images/resized/0010/8066/108066v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President and CEO",
    "person":
     {"first_name": "Christopher",
      "last_name": "A. Kroeger",
      "permalink": "christopher-a-kroeger",
      "image": null}},
   {"is_past": false,
    "title": "Chief Scientific Officer",
    "person":
     {"first_name": "John",
      "last_name": "Reardon",
      "permalink": "john-reardon",
      "image": null}},
   {"is_past": false,
    "title": "director",
    "person":
     {"first_name": "Robert",
      "last_name": "Garland",
      "permalink": "robert-garland",
      "image":
       {"available_sizes":
         [[[110,
            125],
           "assets/images/resized/0026/4917/264917v1-max-150x150.jpg"],
          [[110,
            125],
           "assets/images/resized/0026/4917/264917v1-max-250x250.jpg"],
          [[110,
            125],
           "assets/images/resized/0026/4917/264917v1-max-450x450.jpg"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$42.5M",
 "funding_rounds":
  [{"round_code": "a",
    "source_url": "http://www.cardioxyl.com/news_events/archived_press_releases/cardioxyl_raises_14.5mm_series_a_financing",
    "source_description": "Cardioxyl Raises 14.5MM Series A Financing",
    "raised_amount": 14500000.0,
    "raised_currency_code": "USD",
    "funded_year": 2006,
    "funded_month": 12,
    "funded_day": 6,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "The Aurora Funds",
         "permalink": "the-aurora-funds",
         "image":
          {"available_sizes":
            [[[150,
               34],
              "assets/images/resized/0003/0298/30298v1-max-150x150.png"],
             [[250,
               58],
              "assets/images/resized/0003/0298/30298v1-max-250x250.png"],
             [[271,
               63],
              "assets/images/resized/0003/0298/30298v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "New Enterprise Associates",
         "permalink": "new-enterprise-associates",
         "image":
          {"available_sizes":
            [[[150,
               110],
              "assets/images/resized/0001/5083/15083v3-max-150x150.png"],
             [[150,
               110],
              "assets/images/resized/0001/5083/15083v3-max-250x250.png"],
             [[150,
               110],
              "assets/images/resized/0001/5083/15083v3-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "b",
    "source_url": "http://www.cardioxyl.com/news_events/archived_press_releases/cardioxyl_pr111312",
    "source_description": "Cardioxyl Pharmaceuticals Raises $28 Million in Series B Financing Led by OrbiMed Advisors",
    "raised_amount": 28000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 11,
    "funded_day": 13,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "OrbiMed Advisors",
         "permalink": "orbimed-advisors",
         "image":
          {"available_sizes":
            [[[150,
               42],
              "assets/images/resized/0005/0248/50248v1-max-150x150.png"],
             [[203,
               58],
              "assets/images/resized/0005/0248/50248v1-max-250x250.png"],
             [[203,
               58],
              "assets/images/resized/0005/0248/50248v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "New Enterprise Associates",
         "permalink": "new-enterprise-associates",
         "image":
          {"available_sizes":
            [[[150,
               110],
              "assets/images/resized/0001/5083/15083v3-max-150x150.png"],
             [[150,
               110],
              "assets/images/resized/0001/5083/15083v3-max-250x250.png"],
             [[150,
               110],
              "assets/images/resized/0001/5083/15083v3-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "The Aurora Funds",
         "permalink": "the-aurora-funds",
         "image":
          {"available_sizes":
            [[[150,
               34],
              "assets/images/resized/0003/0298/30298v1-max-150x150.png"],
             [[250,
               58],
              "assets/images/resized/0003/0298/30298v1-max-250x250.png"],
             [[271,
               63],
              "assets/images/resized/0003/0298/30298v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "Exchange East, Suite 212",
    "address2": "1450 Raleigh Road",
    "zip_code": "27517",
    "city": "Chapel Hill",
    "state_code": "NC",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        125],
       "assets/images/resized/0024/2218/242218v1-max-150x150.jpg"],
      [[250,
        209],
       "assets/images/resized/0024/2218/242218v1-max-250x250.jpg"],
      [[450,
        376],
       "assets/images/resized/0024/2218/242218v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}